Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (> 50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1–21 or days 1–7 and 15–21, repeated every 28 days (4 treatment regimens). Responses were seen i...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	Leuk Res
Main Authors:	Erba, Harry P., Othus, Megan, Walter, Roland B., Kirschbaum, Mark H., Tallman, Martin S., Larson, Richard A., Slovak, Marilyn L., Kopecky, Kenneth J., Gundacker, Holly M., Appelbaum, Frederick R.
Format:	Artigo
Sprog:	Inglês
Udgivet:	2013
Fag:	Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4247790/ https://ncbi.nlm.nih.gov/pubmed/24411921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.12.001
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II Study SWOG S0432

Lignende værker